Scholarlink

Background <p>Facioscapolohumeral muscular dystrophy is characterized by a wide clinical variability; the underlying reasons and the relation between them and the genetic markers are still not clear. In fact, the different phenotypes could show a different disease progression and/or imply distinct genetic mechanisms. As clinical trials are approaching also for FSHD, the correct description and stratification of patients becomes mandatory. To address these matters, in 2016 the Italian Clinical Group for FSHD developed the Comprehensive Clinical Evaluation Form (CCEF), aimed at describing the different observed phenotypes in FSHD.</p> Methods <p>A working group composed by the former developers of the CCEF and other expert clinicians re-evaluated the whole structure of the CCEF, to develop a simplified version for use in clinical practice; also, other expert clinicians not referring to the Italian Clinical Group for FSHD read and approved the CCEF revised version for its international use.</p> Results <p>We present the CCEF-R, a revised and simplified version of the CCEF, that while maintaining all the core structure and items of the previous validated version, has been modified with new friendlier graphics, focused on the key anamnestic and neurological examination findings, to facilitate its understanding and use in clinical practice.</p> Conclusions <p>The phenotypical classification combined with the genetic signature should be considered during the diagnostic work out for guiding genetic analysis and for genotype–phenotype correlations and genetic counseling. The CCEF could have a significant role in the clinical stratification process of patients for clinical trials and in laying the groundwork for evidence-based medical decision making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Describing phenotypes in FSHD: an update of the comprehensive clinical evaluation form

  • 期刊论文

  • 发表日期：

    2025年6月13日

查看全文
  • Giulia Ricci,
  • Francesca Torri,
  • Lucia Ruggiero,
  • Liliana Vercelli,
  • Giulio Gadaleta,
  • Enrica Rolle,
  • Barbara Risi,
  • Elena Carraro,
  • Teresinha Evangelista,
  • Enrico Bugiardini,
  • Nicolas Dubuisson,
  • Nicol Voermans,
  • Gabriele Siciliano,
  • Tiziana Mongini,
  • Massimiliano Filosto,
  • Isabella Allegri,
  • Andrea Barp,
  • Roberta Battini,
  • Angela Berardinelli,
  • Michela Coccia,
  • Giacomo Comi,
  • Maurizio Moggio,
  • Monica Sciacco,
  • Maria Grazia D’Angelo,
  • Eleonora Diella,
  • Giovanni Di Muzio,
  • Chiara Fiorillo,
  • Davide Gabellini,
  • Matteo Garibaldi,
  • Giovanni Antonini,
  • Emiliano Giardina,
  • Claudia Strafella,
  • Luca Colantoni,
  • Marina Grandis,
  • Maurizio Inghilleri,
  • Rocco Liguori,
  • Maria Lucia Valentino,
  • Lorenzo Maggi,
  • Isabella Moroni,
  • Roberto Massa,
  • Sabrina Mata’,
  • Vincenzo Nigro,
  • Elena Pegoraro,
  • Corrado Angelini,
  • Antonio Petrucci,
  • Luisa Politano,
  • Stefano Previtali,
  • Alessandra Renieri,
  • Enzo Ricci,
  • Mauro Monforte,
  • Carmelo Rodolico,
  • Cristina Sancricca,
  • Valeria Ada Sansone,
  • Lucio Santoro,
  • Antonio Trabacca,
  • Mara Turri,
  • Rossella Tupler,
  • Gaetano Vattemi,
  • Paola Tonin,
  • Lorenzo Verriello

摘要

Background

Facioscapolohumeral muscular dystrophy is characterized by a wide clinical variability; the underlying reasons and the relation between them and the genetic markers are still not clear. In fact, the different phenotypes could show a different disease progression and/or imply distinct genetic mechanisms. As clinical trials are approaching also for FSHD, the correct description and stratification of patients becomes mandatory. To address these matters, in 2016 the Italian Clinical Group for FSHD developed the Comprehensive Clinical Evaluation Form (CCEF), aimed at describing the different observed phenotypes in FSHD.

Methods

A working group composed by the former developers of the CCEF and other expert clinicians re-evaluated the whole structure of the CCEF, to develop a simplified version for use in clinical practice; also, other expert clinicians not referring to the Italian Clinical Group for FSHD read and approved the CCEF revised version for its international use.

Results

We present the CCEF-R, a revised and simplified version of the CCEF, that while maintaining all the core structure and items of the previous validated version, has been modified with new friendlier graphics, focused on the key anamnestic and neurological examination findings, to facilitate its understanding and use in clinical practice.

Conclusions

The phenotypical classification combined with the genetic signature should be considered during the diagnostic work out for guiding genetic analysis and for genotype–phenotype correlations and genetic counseling. The CCEF could have a significant role in the clinical stratification process of patients for clinical trials and in laying the groundwork for evidence-based medical decision making.